



Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options

Guest Editors:

Dr. Debra Fromer

1. Department of Urology,
Hackensack Meridian School of
Medicine, Nutley, NJ, USA
2. Department of Urology,
Hackensack University Medical
Center, Hackensack, NJ, USA

Dr. Kimberly Cooper

Department of Urology,
Columbia Presbyterian Medical
Center, 161 Fort Washington
avenue, 11th floor, New York, NY
10591, USA

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Urinary tract infections are pervasive, affecting 150 million people worldwide. Affecting 60% of all women at some point in their lives, urinary tract infection is the most common bacterial infection in women, with more than one third of women developing a recurrence, often within 3 months. The sudden, unforeseeable, and distressing nature of the condition takes a significant toll on the patient's mental health, quality of life, and sense of wellbeing. Uropathogens are a significant source of emerging antimicrobial resistance, belying the importance of antibiotic stewardship and emerging antibiotics and non-antibiotic therapies for the treatment and prevention of urinary tract infection. This Special Issue seeks manuscript submissions that further our understanding of the epidemiology of mechanisms of infection and treatment options for urinary tract infection.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)